Upstream Bio, a mid-stage respiratory drug developer, and CAMP4 Therapeutics, a Phase 1 regulatory RNA startup, have unveiled the targeted price ranges for their initial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.